The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor-targeted therapy
The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor-targeted therapy
复制标题
DOI：
10.1002/cncr.26201
复制
发表时间：
2012-01-15
期刊：
影响因子：
6.2
通讯作者：
Choueiri, Toni K.
中科院分区：
文献类型：
--
作者：
Macfarlane, Robyn;Heng, Daniel Y. C.;Choueiri, Toni K.
背景技术背景：进行了一项研究，以研究基线肾功能对接受血管内皮生长因子（VEGF）靶向治疗的转移性肾细胞癌（mRCC）患者治疗结局的影响。方法：汇总了来自6个北美癌症中心（3个美国和3个加拿大）的回顾性数据，以确定接受VEGF靶向治疗的mRCC患者。收集患者特征、缓解率、治疗失败时间和总生存期。在治疗开始时使用肾脏疾病饮食改良公式计算肾小球滤过率（GFR）。研究结果：529例接受舒尼替尼（n=323）、索拉非尼（n=165）或贝伐单抗（n=41）治疗的mRCC患者纳入本分析。患者特征包括：74%为男性，中位年龄61岁，中位GFR 60.1 mL/min/1.73 m（2）（范围6.5-174.2）。单变量分析显示，GFR < 60的患者（n=262）更有可能接受过肾切除术（P
BACKGROUND: A study was undertaken to investigate the effect of baseline renal function on treatment outcome in patients treated with vascular endothelial growth factor (VEGF)-targeted therapy for metastatic renal cell carcinoma (mRCC). METHODS: Retrospective data from 6 North American cancer centers (3 US and 3 Canadian) were pooled to identify patients with mRCC treated with VEGF-targeted therapy. Patient characteristics, response rate, time to treatment failure, and overall survival were collected. The Modification of Diet in Renal Disease formula was used at therapy initiation for calculation of glomerular filtration rate (GFR). RESULTS: Five hundred twenty-nine patients with mRCC who received sunitinib (n=323), sorafenib (n=165), or bevacizumab (n=41) were included in this analysis. Patient characteristics included: 74% male, median age 61 years, and median GFR 60.1 mL/min/1.73 m(2) (range, 6.5-174.2). On univariate analysis, patients with a GFR < 60 (n=262) were more likely to have had a previous nephrectomy (P